- Home
- MLP vs AVTX Comparison
MLP vs AVTX Comparison
Compare MLP & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLP | AVTX |
|---|---|---|
| Founded | 1909 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.2M | 248.3M |
| IPO Year | 1972 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MLP | AVTX |
|---|---|---|
| Price | $16.81 | $20.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.14 |
| AVG Volume (30 Days) | 40.9K | ★ 362.6K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,344,000.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.55 | N/A |
| 52 Week Low | $13.84 | $3.39 |
| 52 Week High | $23.41 | $20.45 |
Technical Indicators
Market Signals| Indicator | MLP | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 63.04 |
| Support Level | $16.05 | $15.53 |
| Resistance Level | $17.14 | $20.45 |
| Average True Range (ATR) | 0.63 | 1.47 |
| MACD | 0.21 | 0.15 |
| Stochastic Oscillator | 86.02 | 89.84 |
Price Performance
Historical ComparisonAbout MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).